PL2022501T3 - Wykorzystanie fitynianu jako środka wpływającego na rozpuszczanie kryształów soli wapnia w celu zapobiegania osteoporozie i leczenia jej - Google Patents

Wykorzystanie fitynianu jako środka wpływającego na rozpuszczanie kryształów soli wapnia w celu zapobiegania osteoporozie i leczenia jej

Info

Publication number
PL2022501T3
PL2022501T3 PL07765887T PL07765887T PL2022501T3 PL 2022501 T3 PL2022501 T3 PL 2022501T3 PL 07765887 T PL07765887 T PL 07765887T PL 07765887 T PL07765887 T PL 07765887T PL 2022501 T3 PL2022501 T3 PL 2022501T3
Authority
PL
Poland
Prior art keywords
phytate
osteoporosis
crystals
prevention
treatment
Prior art date
Application number
PL07765887T
Other languages
English (en)
Inventor
Felix Grases Freixedas
Pilar Sanchis Cortes
Antonia COSTA-BAUZÁ
Joan PERELLÓ BESTARD
Rafael Mará PRIETO ALMIRALL
Bernat Isern Amengual
Ramón GARCÍA GONZÁLEZ
Original Assignee
Universitat De Les Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat De Les Illes Balears filed Critical Universitat De Les Illes Balears
Publication of PL2022501T3 publication Critical patent/PL2022501T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07765887T 2006-06-01 2007-05-30 Wykorzystanie fitynianu jako środka wpływającego na rozpuszczanie kryształów soli wapnia w celu zapobiegania osteoporozie i leczenia jej PL2022501T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200601519A ES2288126B2 (es) 2006-06-01 2006-06-01 Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
PCT/ES2007/070102 WO2007138147A1 (es) 2006-06-01 2007-05-30 Utilización de fitato como agente inhibidor de la disolución de cristales de sales cálcicas para la prevención de la osteoporosis
EP07765887.0A EP2022501B1 (en) 2006-06-01 2007-05-30 Use of phytate as agent inhibiting dissolution of crystals of calcium salts for the prevention and treatment of osteoporosis

Publications (1)

Publication Number Publication Date
PL2022501T3 true PL2022501T3 (pl) 2020-03-31

Family

ID=38778157

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07765887T PL2022501T3 (pl) 2006-06-01 2007-05-30 Wykorzystanie fitynianu jako środka wpływającego na rozpuszczanie kryształów soli wapnia w celu zapobiegania osteoporozie i leczenia jej

Country Status (13)

Country Link
US (1) US8377909B2 (pl)
EP (1) EP2022501B1 (pl)
JP (1) JP2009538883A (pl)
CN (2) CN101484174A (pl)
AU (1) AU2007266983B2 (pl)
CA (1) CA2654281C (pl)
DK (1) DK2022501T3 (pl)
ES (2) ES2288126B2 (pl)
MX (1) MX2008015205A (pl)
NO (1) NO344167B1 (pl)
PL (1) PL2022501T3 (pl)
PT (1) PT2022501T (pl)
WO (1) WO2007138147A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US9364490B2 (en) 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
US11707470B2 (en) 2015-12-11 2023-07-25 Eth Zurich Inositol derivatives for use in pathological crystallization
US11028112B2 (en) 2015-12-11 2021-06-08 Eth Zurich Inositol derivatives for use in pathological crystallization
DK3386548T3 (da) * 2015-12-11 2021-05-25 Eth Zuerich Inositol-derivater til anvendelse i patologisk krystallisering
DE102016013737A1 (de) 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
KR102666724B1 (ko) * 2017-10-26 2024-05-20 오츠카 세이야쿠 가부시키가이샤 이노시톨인산 함유 조성물
EP3556728A1 (en) 2018-04-16 2019-10-23 Croda Denmark A/S Organically modified mineral micro-particles, methods of preparing the same and uses thereof
CA3113377A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
MX2021008966A (es) 2019-01-30 2021-11-04 Sanifit Therapeutics S A Compuestos de fosfato de inositol para su uso en el aumento de la perfusion tisular.
EP3818983A1 (en) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
EP4015494A1 (en) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Processes for the preparation of soluble salts of inositol phosphates
EP4036097A1 (en) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Ip4-4,6 substituted derivative compounds
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
AU2023313374A1 (en) 2022-07-29 2025-02-13 Vifor (International) Ltd. Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2025162971A1 (en) 2024-01-31 2025-08-07 Sanifit Therapeutics, S.A. Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015634A (en) 1986-04-16 1991-05-14 Perstorp Ab Method of treating tissue damage with inositol triphosphate
US5057507A (en) 1986-04-16 1991-10-15 Perstorp Ab Method of alleviating bone damage with inositoltriphosphate
SE8904355D0 (sv) 1989-12-21 1989-12-21 Perstorp Ab Medicament
JP3320359B2 (ja) * 1998-06-09 2002-09-03 太子食品工業株式会社 有機態亜鉛を添加した食品
ES2152899B1 (es) * 1999-07-16 2002-03-16 Univ Illes Balears Aplicacion de harinas de germen de ciertos cereales en la fabricacion de productos alimenticios utiles para el tratamiento de estados carenciales en fitatos.
CN1120725C (zh) 1999-11-12 2003-09-10 高同祥 治疗骨质疏松、增生的药物及其制备方法
DE60335195D1 (de) * 2002-08-12 2011-01-13 Danisco Us Inc Mutante e. coli-appa-phytaseenzyme und natürliche varianten davon, solche phytaseenzyme codierende nukleinsäuren, diese enthaltende vektoren und wirtszellen und verfahren zur herstellung und verwendung davon
JP4595080B2 (ja) * 2003-09-25 2010-12-08 学校法人明治大学 セメント用材料およびセメント
ES2232302B1 (es) * 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
GB0517466D0 (en) * 2005-08-26 2005-10-05 Immunodiagnostic Systems Plc Diagnostic assay and therapeutic treatment
US20070212449A1 (en) * 2006-03-02 2007-09-13 Shamsuddin Abulkalam M Reduction of the titratable acidity and the prevention of tooth and other bone degeneration
JP2007302600A (ja) * 2006-05-11 2007-11-22 Kaneka Corp イネ属植物材料由来の骨代謝改善用組成物とその製造方法

Also Published As

Publication number Publication date
BRPI0711506A2 (pt) 2011-11-01
CN101484174A (zh) 2009-07-15
NO20085374L (no) 2009-03-02
ES2748108T3 (es) 2020-03-13
ES2288126B2 (es) 2009-07-06
DK2022501T3 (da) 2019-11-04
MX2008015205A (es) 2009-03-12
EP2022501B1 (en) 2019-08-14
CN103908455A (zh) 2014-07-09
EP2022501A4 (en) 2009-11-11
AU2007266983B2 (en) 2011-10-13
CA2654281A1 (en) 2007-12-06
WO2007138147A1 (es) 2007-12-06
CA2654281C (en) 2013-12-24
US8377909B2 (en) 2013-02-19
JP2009538883A (ja) 2009-11-12
PT2022501T (pt) 2019-11-06
AU2007266983A1 (en) 2007-12-06
NO344167B1 (no) 2019-09-23
EP2022501A1 (en) 2009-02-11
ES2288126A1 (es) 2007-12-16
US20090203650A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
PL2022501T3 (pl) Wykorzystanie fitynianu jako środka wpływającego na rozpuszczanie kryształów soli wapnia w celu zapobiegania osteoporozie i leczenia jej
IL193484A0 (en) Gsk-3 inhibitors for the treatment of osteoporosis
GB2453188B (en) Use of compounds in the manufacture of medicaments for treatment of regional fat deposits
AP2579A (en) Thiophene analogues for the treatment or prevention of flavivirus infections
IL194153A0 (en) Compounds for the treatment of spinal muscular atrophy and other uses
IL207713A0 (en) Formulation and method for the prevention and treatment of bone metastases or other bone diseases
IL198182A0 (en) Use of citrulline for treating undernutrition conditions
IL187565A0 (en) Compositions and methods for the treatment or prevention of chemoresistant neoplasia
PL1685834T3 (pl) Zastosowanie kwasu pinolenowego do leczenia otyłości
IL195971A0 (en) Use of defibrotide for the inhibition of heparanase
GB0909297D0 (en) Composition for the treatment of skin conditions
PL1732575T3 (pl) Związki zawierające stron do stosowania w zapobieganiu lub leczeniu stanów nekrotycznych kości
PL1905452T3 (pl) Środek do zapobiegania lub leczenia jaskry
IL186021A0 (en) Oxaprozin or closely related compound for the treatment and prevention of pruritus
EP2056830A4 (en) SPECIAL COMPOSITIONS FOR TREATMENT OR PREVENTION OF METABOLIC SYNDROME
IL197533A (en) Calcium formate for use in the treatment or prevention of chewing gum
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
IL200668A0 (en) Novel preventive and/or therapeutic agent for neuropathic pain
IL201466A0 (en) Use of hdac inhibitors for the treatment of bone destruction
ZA200807068B (en) Corrosion inhibitor treatment for closed loop system
EP2266578A4 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von knochenresorption unterschiedlicher ätiologie
LT2380587T (lt) C1 inhibitoriaus naudojimas išeminio-reperfuzinio pažeidimo prevencijai
TWI365073B (en) Pharmaceutical composition for prevention and/or treatment of bone loss
ZA200708278B (en) Oxaprozin or closely related compound for the treatment and prevention of pruritus
IL198344A0 (en) Use of mtki 1 for treating or preventing bone cancer